JP4212113B2 - サイクロスポリン乳剤 - Google Patents
サイクロスポリン乳剤 Download PDFInfo
- Publication number
- JP4212113B2 JP4212113B2 JP53536797A JP53536797A JP4212113B2 JP 4212113 B2 JP4212113 B2 JP 4212113B2 JP 53536797 A JP53536797 A JP 53536797A JP 53536797 A JP53536797 A JP 53536797A JP 4212113 B2 JP4212113 B2 JP 4212113B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- cyclosporine
- emulsion
- phospholipid
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 64
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 63
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 62
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 55
- 239000000839 emulsion Substances 0.000 title claims description 32
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 21
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 18
- 239000012071 phase Substances 0.000 claims abstract description 18
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000007764 o/w emulsion Substances 0.000 claims abstract description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008346 aqueous phase Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003921 oil Substances 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 14
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000002736 nonionic surfactant Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- 229960004488 linolenic acid Drugs 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical group CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 235000019198 oils Nutrition 0.000 description 23
- 150000003626 triacylglycerols Chemical class 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 235000020778 linoleic acid Nutrition 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000002563 ionic surfactant Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- -1 MIGLYOL 810 Chemical class 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/627,187 US5660858A (en) | 1996-04-03 | 1996-04-03 | Cyclosporin emulsions |
| US08/627,187 | 1996-04-03 | ||
| PCT/US1997/004794 WO1997036611A1 (en) | 1996-04-03 | 1997-03-26 | Cyclosporin emulsions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000509021A JP2000509021A (ja) | 2000-07-18 |
| JP2000509021A5 JP2000509021A5 (https=) | 2004-11-18 |
| JP4212113B2 true JP4212113B2 (ja) | 2009-01-21 |
Family
ID=24513586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53536797A Expired - Fee Related JP4212113B2 (ja) | 1996-04-03 | 1997-03-26 | サイクロスポリン乳剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5660858A (https=) |
| EP (1) | EP0799620B1 (https=) |
| JP (1) | JP4212113B2 (https=) |
| AT (1) | ATE260673T1 (https=) |
| AU (1) | AU2588597A (https=) |
| CA (1) | CA2250970C (https=) |
| DE (1) | DE69727849T2 (https=) |
| ES (1) | ES2217368T3 (https=) |
| WO (1) | WO1997036611A1 (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19537012A1 (de) * | 1995-10-04 | 1997-04-10 | Dietl Hans | Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung |
| US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6281175B1 (en) | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
| US6054421A (en) * | 1997-09-23 | 2000-04-25 | Scimed Life Systems, Inc. | Medical emulsion lubricant |
| DE19810655A1 (de) * | 1998-03-12 | 1999-09-16 | Univ Eberhard Karls | Arzneimittel mit einem Gehalt an Ciclosporin |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| HK1039458B (zh) | 1998-05-29 | 2006-09-01 | Skyepharma Canada Inc. | 熱保護微粒組合物及其最終蒸汽滅菌的方法 |
| US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| ES2211151T3 (es) | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
| SK288117B6 (sk) | 1998-11-20 | 2013-09-03 | Skyepharma Canada Inc. | Rapidly dispersing solid dry therapeutic dosage form |
| EP1154759B1 (en) | 1998-12-30 | 2008-08-13 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| AU7638300A (en) * | 1999-10-20 | 2001-04-30 | Vesifact Ag | Microemulsion preconcentrates and microemulsions |
| US20050037086A1 (en) * | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| DE19961733A1 (de) * | 1999-12-21 | 2001-06-28 | Ciclomulsion Ag | Cyclosporin(e) enthaltende hypertone pharmazeutische Zubereitung zur Anwendung bei neurologischen Erkrankungen und als Neuroprotektivum sowie Verfahren zu ihrer Herstellung |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| DE10030378A1 (de) * | 2000-06-21 | 2002-03-14 | Audit Inst For Medical Service | Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen |
| DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US6869617B2 (en) * | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| JP2005504090A (ja) | 2001-09-26 | 2005-02-10 | バクスター・インターナショナル・インコーポレイテッド | 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製 |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| HRP20040354B1 (en) * | 2001-10-19 | 2012-10-31 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| HUP0402318A3 (en) * | 2001-12-14 | 2012-09-28 | Jagotec Ag | Pharmaceutical composition comprising cyclosporin and use thereof |
| RU2301679C2 (ru) * | 2001-12-14 | 2007-06-27 | Яготек Аг | Фармацевтический препарат, содержащий циклоспорин, и его применение |
| US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| JP2007520555A (ja) * | 2004-02-05 | 2007-07-26 | バクスター・インターナショナル・インコーポレイテッド | 自己安定化剤の使用により調製された分散剤 |
| US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| US11311477B2 (en) * | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| EP2049081B1 (en) | 2006-08-09 | 2012-11-14 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| WO2008070538A2 (en) * | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
| SG10201607909WA (en) * | 2006-12-01 | 2016-11-29 | Anterios Inc | Peptide nanoparticles and uses therefor |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| US20080234232A1 (en) * | 2007-03-20 | 2008-09-25 | Flynn Daniel C | Methods and compositions for targeting AFAP |
| JP5135852B2 (ja) | 2007-03-30 | 2013-02-06 | 日油株式会社 | 可溶化用組成物 |
| HRP20130259T1 (hr) | 2007-04-23 | 2013-04-30 | Intarcia Therapeutics, Inc. | Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe |
| TW200904485A (en) * | 2007-05-18 | 2009-02-01 | Alcon Res Ltd | Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions |
| US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| EP2008651A1 (en) | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
| MX340897B (es) | 2007-10-02 | 2016-07-29 | Theranos Inc | Dispositivos modulares de punto de cuidado y usos de los mismos. |
| DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
| TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
| AU2010203607A1 (en) * | 2009-01-08 | 2011-07-21 | Allergan, Inc. | Cyclosporine compositions for enhancing nail growth |
| SMT201700583T1 (it) | 2009-09-28 | 2018-01-11 | Intarcia Therapeutics Inc | Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario |
| ES2643862T3 (es) * | 2009-11-17 | 2017-11-24 | Michael Anthony Folan | Composiciones antimicrobianas que contienen ácidos grasos libres |
| JP2012051823A (ja) * | 2010-08-31 | 2012-03-15 | Fujifilm Corp | 難容性薬物含有水中油型乳化組成物及びその製造方法 |
| WO2012069149A1 (en) * | 2010-11-23 | 2012-05-31 | Merck Patent Gmbh | Solution comprising cyclic oligopeptides |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9610245B2 (en) | 2011-03-14 | 2017-04-04 | Drug Delivery Solutions Limited | Ophthalmic composition |
| KR101492447B1 (ko) | 2013-05-20 | 2015-02-23 | 주식회사태준제약 | 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법 |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| RU2760007C2 (ru) | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Полипептиды, селективные к рецепторам глюкагона, и способы их применения |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| AU2017360346B2 (en) | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1165238A (en) * | 1980-03-12 | 1984-04-10 | Demetrios P. Papahadjopoulos | Activated liposomes and method |
| AU609242B2 (en) * | 1988-01-29 | 1991-04-26 | Novartis Ag | Cyclosporin compositions |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| CA1337397C (en) * | 1988-09-29 | 1995-10-24 | Hideo Nakajima | Emulsified composition |
| AU614465B2 (en) * | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| JP2785981B2 (ja) * | 1989-11-20 | 1998-08-13 | 株式会社資生堂 | 乳化組成物 |
| US5529785A (en) * | 1993-05-12 | 1996-06-25 | Dietl; Hans | Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same |
| EP0570829B1 (de) * | 1992-05-18 | 2001-04-25 | CicloMulsion AG | Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung |
| WO1994008603A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Compositions |
| WO1994008605A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Therapeutic microemulsions |
| DE4338086A1 (de) * | 1993-11-08 | 1995-05-11 | Dietl Hans | Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur oralen Applikation sowie Verfahren zu ihrer Herstellung |
| GB9601120D0 (en) * | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
-
1996
- 1996-04-03 US US08/627,187 patent/US5660858A/en not_active Expired - Lifetime
-
1997
- 1997-03-26 AU AU25885/97A patent/AU2588597A/en not_active Abandoned
- 1997-03-26 WO PCT/US1997/004794 patent/WO1997036611A1/en not_active Ceased
- 1997-03-26 CA CA2250970A patent/CA2250970C/en not_active Expired - Fee Related
- 1997-03-26 JP JP53536797A patent/JP4212113B2/ja not_active Expired - Fee Related
- 1997-04-03 ES ES97302298T patent/ES2217368T3/es not_active Expired - Lifetime
- 1997-04-03 AT AT97302298T patent/ATE260673T1/de not_active IP Right Cessation
- 1997-04-03 DE DE69727849T patent/DE69727849T2/de not_active Expired - Lifetime
- 1997-04-03 EP EP97302298A patent/EP0799620B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE260673T1 (de) | 2004-03-15 |
| JP2000509021A (ja) | 2000-07-18 |
| DE69727849T2 (de) | 2004-07-29 |
| ES2217368T3 (es) | 2004-11-01 |
| WO1997036611A1 (en) | 1997-10-09 |
| US5660858A (en) | 1997-08-26 |
| EP0799620B1 (en) | 2004-03-03 |
| CA2250970A1 (en) | 1997-10-09 |
| CA2250970C (en) | 2012-10-16 |
| EP0799620A1 (en) | 1997-10-08 |
| DE69727849D1 (de) | 2004-04-08 |
| AU2588597A (en) | 1997-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4212113B2 (ja) | サイクロスポリン乳剤 | |
| JP6741655B2 (ja) | アプレピタントのエマルジョン製剤 | |
| EP0361928B1 (en) | Emulsified composition | |
| AU712621B2 (en) | Lipid vehicle drug delivery composition containing vitamin E | |
| US6599527B1 (en) | Preparation of pharmaceutical compositions | |
| EP0711550B1 (en) | Cyclosporin-containing soft capsule compositions | |
| JP5603852B2 (ja) | 凍結乾燥ナノエマルション | |
| JPH08511245A (ja) | 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体 | |
| WO1997030695A1 (en) | Drug delivery compositions suitable for intravenous injection | |
| JP2005225818A (ja) | パクリタキセル又はドセタキセルの医薬組成物 | |
| JPH02502719A (ja) | 薬理学的剤‐脂質溶液製剤 | |
| JPWO2006098241A1 (ja) | 難水溶性薬物を含有する医薬組成物 | |
| TW200526200A (en) | Therapeutic compositions | |
| JPH0145446B2 (https=) | ||
| Gupta et al. | for Drug Solubilization and Delivery | |
| WO2006123354A2 (en) | Oral pharmaceutical composition | |
| JPH01113315A (ja) | ビタミンｋ↓２含有脂肪乳剤 | |
| KR20060108668A (ko) | 피라졸-3-카르복스아미드 유도체의 경구 투여용 제약조성물 | |
| WO2000002534A1 (fr) | Kit a preparer avant usage avec preparation contenant un medicament et solvant destine a cette fin | |
| JP2002540158A (ja) | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン | |
| WO2005065676A1 (ja) | パクリタキセルまたはドセタキセルを含む脂肪乳剤 | |
| Kumar et al. | Review on Emulsomes as Carriers for Drug Delivery | |
| CA2991084A1 (en) | Propofol emulsion for parenteral administration | |
| Cannon et al. | 10 Emulsions, Microemulsions, and Lipid-Based Drug | |
| WO2005065677A1 (ja) | パクリタキセルまたはドセタキセルを溶解または分散させるための脂肪乳剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080116 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080218 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080317 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080804 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080930 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081028 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111107 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121107 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131107 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |